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Abstract
Introduction: Beta‐cell autoantibodies are established markers of auto-
immunity, which we compared between Ghanaian adults with or without
diabetes, living in rural and urban Ghana and in three European cities.
Methods: In the multicenter cross‐sectional Research on Obesity and Diabetes
among African Migrants (RODAM) study (N = 5898), we quantified auto-
antibodies against glutamic acid decarboxylase (GAD65Ab) by radioligand
binding assay (RBA) and established cut‐offs for positivity by displacement
analysis. In a subsample, we performed RBA for zinc transporter‐8 auto-
antibodies (ZnT8Ab). Associations of environmental, sociodemographic, and
clinical factors with GAD65Ab were calculated.
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Results: In this study population (age: 46.1 ± 11.9 years; female: 62%;
Ghana‐rural: 1111; Ghana‐urban: 1455; Europe: 3332), 9.2% had diabetes
with adult‐onset. GAD65Ab concentrations were the highest in Ghana‐rural
(32.4; 10.8‐71.3 U/mL), followed by Ghana‐urban (26.0; 12.3‐49.1 U/mL) and
Europe (11.9; 3.0‐22.8 U/mL) with no differences between European cities.
These distributions were similar for ZnT8Ab. Current fever, history of fever,
and higher concentrations of liver enzymes marginally explained site‐specific
GAD65Ab concentrations. GAD65Ab positivity was as frequent in diabetes as
in nondiabetes (5.4% vs 6.1%; P= .25). This was also true for ZnT8Ab positivity.
Conclusion: Geographic location determines the occurrence of GAD65Ab and
ZnT8Ab more than the diabetes status. Beta‐cell autoimmunity may not be
feasible to differentiate diabetes subgroups in this population.
KEYWORD S
diabetes mellitus, Ghana, glutamic acid decarboxylase autoantibodies, migration,
zinc transporter‐8 autoantibodies
1 | INTRODUCTION
Diabetes mellitus (henceforth, diabetes) constitutes a
major challenge for international health. According to
the World Health Organization (WHO), the number of
adults with diabetes has doubled to 422 million between
1980 and 2014.1 While this rapid increase has largely
been attributed to the emergence of type 2 diabetes in
low‐ and middle‐income countries, the distinction be-
tween the major diabetes subtypes is not trivial. This
might be particularly true for Africans in their country of
origin and for African migrants in Europe; both groups
are disproportionately affected by diabetes.2 Con-
ventionally, the disease etiology determines diabetes
subclassification and disease management.3 Type 1 dia-
betes is characterized by beta‐cell destruction and auto-
immunity, and type 2 diabetes results from insulin
resistance and/or insulin secretory defects.3 However,
there is an overlap between these subtypes. In many non‐
African populations, 5% to 10% of persons classified as
type 2 diabetes are positive for autoantibodies directed
against the beta‐cell autoantigen, glutamic acid dec-
arboxylase 65 (GAD65Ab); this subgroup has been
named latent autoimmune diabetes in adults (LADA).4
Moreover, even newer subtypes of adult‐onset diabetes
have been proposed, including an adult autoimmune
subtype.5 Thus, GAD65Ab are established sensitive and
specific biomarkers of autoimmunity for newly diagnosed
type 1 diabetes (T1D) at a young age and for adult‐onset
autoimmune diabetes,6‐8 including LADA.
The occurrence of GAD65Ab constitutes an essential
decision criterion for diabetes management,9 predicts
the rate of C‐peptide loss and the need for insulin
treatment.10 Still, the utility of GAD65Ab for the identi-
fication of autoimmune diabetes for both, Africans in
their home country and African migrants in Europe, has
rarely been addressed. The few previous studies may not
reflect the populations’ health care needs, because these
were not population‐based samples.11‐13
Therefore, we aimed at determining the population‐
specific GAD65Ab prevalence as a marker for autoimmune
diabetes among a representative sample of Ghanaian
adults, and identifying the relationships with geographic
location, sociodemographic and clinical factors.
2 | MATERIALS AND METHODS
2.1 | Study design and study population
The study protocol and procedures of the Research on
Obesity and Diabetes among African Migrants (RODAM)
study have been published elsewhere.14 In brief, this mul-
ticenter cross‐sectional study was conducted among
Ghanaian adults (N= 6385; age range, 25‐70 years) in rural
Ghana, urban Ghana, and Europe (Amsterdam, London,
and Berlin) between July 2012 and September 2015. Re-
sponse rates were 76% in rural Ghana, 74% in urban Ghana,
53% in Amsterdam, 75% in London, and 68% in Berlin.14
All blood samples were collected, handled, processed,
and stored according to standardized procedures and were
analyzed in the same laboratory in Berlin (Charité). In this
cross‐sectional study, diabetes was defined as fasting
plasma glucose (FPG)≥ 7.0mmol/L or documented
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glucose‐lowering medication or self‐reported diabetes.
Medical history, lifestyle, and socioeconomic factors were
recorded either by an ethnically matched staff in
questionnaire‐based interviews or by self‐report.
2.2 | Ethics statement
The RODAM study was conducted according to the
guidelines laid down in the 1964 Declaration of Helsinki
and its later amendments. All procedures involving
human subjects were reviewed and approved by the
respective ethics committees in Ghana, the Netherlands,
the United Kingdom, and Germany. Written informed
consent was obtained from all participants.
2.3 | Questionnaire‐based interviews
Sociodemographic data were collected as previously
described14 and included age, sex, length of stay in
Europe, and educational level. Self‐reported medical
history included age at diabetes diagnosis, family history
of diabetes, type of diabetes medication (lifestyle, oral,
insulin), insulin treatment immediately at diabetes diag-
nosis, insulin treatment within 6 months after diabetes
diagnosis, current fever, and history of fever within the
last 2 weeks. Smoking was categorized into current and
former smokers or nonsmokers.
2.4 | Anthropometric measurements
Anthropometric measures were taken in light clothing
without shoes and to the nearest decimal. Weight was
assessed with a person scale (SECA 877; SECA, Germany)
and standing height with a portable stadiometer (SECA
217; SECA, Germany). Waist circumference was measured
with a measuring tape. Body mass index (BMI) was
calculated as weight (kg) divided by height (m2).
2.5 | Biological sample processing and
clinical biomarkers
Fasting venous blood samples were collected and ali-
quoted immediately after collection according to standard
operating procedures and temporarily stored at −20°C.
First early morning urine was collected. The separated
blood samples and urine samples were stored at −80°C.
FPG, C‐reactive protein (CRP), liver enzymes (aspartate
aminotransferase [ASAT], alanine aminotransferase
[ALAT], γ‐glutamyltransferase [GGT]), and biomarkers of
kidney function (creatinine and urinary albumin) were
measured using an ABX Pentra 400 Chemistry Analyzer
(HORIBA ABX, Montpellier, France). For diabetes defi-
nition, we applied FPG because of the questionable utility
of HbA1c in populations with frequent hemoglobino-
pathies and conditions that reduce erythrocyte lifespan.
The estimated glomerular filtration rate (eGFR; mL/min/
1.73m2) was calculated using the abbreviated Modification
of Diet in Renal Disease (MDRD) formula: 186 × (creati-
nine in mg/dL)− 1.154 × (age in years)− 0.203 × (0.742, if
female) × (1.212, if African). Insulin concentrations were
assessed using the Mercodia ELISA kit (Mercodia,
Uppsala, Sweden) with a lower detection limit of 76 pmol/L.
HbA1c (mmol/mol) was determined using the TOSOH G8
HPLC Analyzer (TOSOH Bioscience, Tokyo, Japan).
2.6 | Measurements of beta‐cell
autoantibodies
GAD65Ab was analyzed in all 5898 samples by radi-
oligand binding assay (RBA) as previously described.15
Antibody levels were expressed as a relative index to
correct for inter‐assay variation using the WHO stan-
dard for GAD65Ab.16 To determine the relative index,
positive and negative control samples were included in
all assays. The assay showed 70% sensitivity and 98%
specificity for GAD65Ab in the International Combined
Autoantibody Workshop.17 For statistical analyses and
comparability, the index was translated into U/mL
(Index 1 = 1000 U/mL).
To establish specific cut‐off values for GAD65Ab posi-
tivity in this population, we refrained from using arbitrary
cut‐offs that are highly laboratory specific. Rather, a com-
petition assay was performed in 59 participants in Ghana
without diabetes and in 58 participants in Europe without
diabetes, employing recombinant human (rh) GAD65
(Diamyd Medical, Sweden).18 The samples were incubated
with [35S]‐GAD65 in the absence or presence of rhGAD65
(200 ng/mL). Samples whose binding to [35S]‐GAD65 were
reduced by 40% in the presence of rhGAD65 were con-
sidered as having specific GAD65Ab (true positive)
(Figure S1). This binding strength was achieved at higher
GAD65Ab concentrations in samples from Ghana than in
samples from Europe, and was set as the gold standard in
subsequent receiver operating characteristic analysis
(Figure S2). At 78% sensitivity and 70% specificity, the
GAD65Ab cut‐offs were 121 and 97U/mL for the Ghanaian
and European study sites, respectively.
In subsamples, we assessed the robustness of
GAD65Ab detection using alternative laboratory methods
(Table S1). These methods used for GAD65Ab detection
include (a) enzyme‐linked immunosorbent assay (ELISA)
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using a kit by Kronus (Boise) (n = 124), (b) ELISA using a
kit by DRG International Inc (n = 84), and (c) luciferase
immunoprecipitation system (LIPS) (n = 140) performed
in an independent laboratory at Helmholtz Centre
Munich, Germany.19 Also, we measured zinc transporter‐8
autoantibody (ZnT8Ab) as a novel marker for autoimmune
diabetes. ZnT8Ab was measured under similar conditions as
described for GAD65Ab with constructs containing the cy-
tosolic segments (aa268‐369) encoding the aa325 codon
variants, CGG (T) and TGG (W). Results for ZnT8Ab were
converted into arbitrary units by extrapolation using a
pan‐reactive positive serum from a patient with T1D with
designated 1000 arbitrary units. Cut‐off was set at 10U/mL
for autoantibodies to ZnT8R and 18U/mL for ZnT8W based
on the 98th percentile observed in 162 individuals without
diabetes.
Lastly, isotype‐specific identification of immunoglobulins
(Ig) was performed using an ELISA (Bio‐Rad) in 316 samples
(rural Ghana: n= 124; Europe: n= 192) to account for iso-
type shifts during different phases of the humoral immune
response. Specifically, we measured total IgG 1, 2, 3, 4, IgE,
IgA, and IgM. This analysis was performed because the RBA
for GAD65Ab measurement does not discriminate
GAD65Ab of different Ig isotypes.
2.7 | Statistical analysis
Figure S3 shows the flow chart of imputed data, resulting
in a final analytical sample size of 5898 participants.
Multiple imputations were applied to estimate the
missing values (n = 10; discriminant fully conditional
specification method; relative efficiency: 97%‐99%). The
characteristics of the study population are presented as
mean ± standard deviation for normally distributed con-
tinuous variables, as median (interquartile range [IQR])
for non‐normally distributed continuous variables, and as
the number of individuals (percentage) for categorical
data. Comparisons across study sites and by diabetes
status were made by Student's t test, the Wilcoxon rank‐
sum test, and χ2 test, respectively. Spearman correlations
were used to investigate the relationships of GAD65Ab
concentrations between different assays and with differ-
ent isotypes. Next, we examined associations of place of
residence, sociodemographic and clinical factors with
GAD65Ab concentrations. Linear regression models were
used to calculate adjusted means of GAD65Ab con-
centrations with their 95% confidence intervals. Study
site and length of stay in Europe were included as im-
portant sociodemographic factors. Clinically relevant
factors comprised duration of diabetes and insulin treat-
ment. Particularly, we hypothesized that infectious
agents may serve as potential environmental triggers for
islet autoimmunity11,20,21 and explored the following
factors: CRP, current fever, history of fever in the past
2 weeks, ALAT, ASAT, ASAT‐ALAT ratio, GGT, eGFR,
and urinary albumin. The regression models were ad-
justed for age and sex (model 1), and additionally for
education, BMI, waist circumference, and smoking status
(model 2). In model 3, we further included infection‐
related factors to assess whether they will mitigate the
differences in GAD65Ab concentrations between study
sites. By using a sensitivity analysis, we repeated the
comparison by place of residence and diabetes status
excluding individuals with self‐reported diabetes.
All analyses were performed using SAS 6.1 (SAS In-
stitute Inc, Cary) and a 2‐sided P< .05 was considered
statistically significant.
3 | RESULTS
3.1 | General characteristics
Table S2 displays the characteristics of the study popula-
tion according to sex and place of residence. The mean age
of the study population was 46.1 ± 11.9 years and the
majority was female (62%). Individuals in Europe were
mainly first‐generation migrants (98%) and their mean
length of stay in Europe was 17.3 ± 8.8 years. Most parti-
cipants had a lower or intermediate education (71%) and
worked in manual jobs (68%). With regard to diabetes, the
crude prevalence was 9.2% in the total study population,
and the vast majority had an adult disease onset (median:
48 years; IQR: 40‐54 years). Diabetes was more common in
men than in women (11% vs 8%), and more frequent in
migrants than in nonmigrants (Europe: 11%, urban
Ghana: 9%, rural Ghana: 5%). More than two‐thirds
(69%) were reported to have diabetes, and 58% had an
FPG≥ 7mmol/L. The median duration of diabetes was
5.0 years (IQR: 1.0‐11.0 years) and this was similar be-
tween study sites. Fifty‐four percent of the diabetes
patients received medication: oral glucose‐lowering drugs
(80%), lifestyle therapy (55%), and insulin treatment (15%).
3.2 | GAD65Ab across study sites
Figure 1 shows that individuals in rural Ghana had the
highest GAD65Ab concentrations (median: 32.4; IQR:
10.8‐71.3U/mL), followed by urban Ghana (median: 26.0;
IQR: 12.3‐49.1U/mL; P= .002) and Europe (median: 11.9;
IQR: 3.0‐22.8U/mL; P< .0001). No differences in GAD65Ab
concentrations were seen between Amsterdam (median:
12.7; IQR: 4.2‐23.0U/mL), London (median: 8.4; IQR:
0.3‐20.2U/mL) or Berlin (median: 15.9; IQR: 7.4‐26.1U/mL).
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Therefore, we combined the European study sites in
the following analyses. Correspondingly, the proportions
of individuals with GAD65Ab positivity was the highest
in rural Ghana, followed by urban Ghana and Europe
(Table 1).
The results obtained by the Kronus ELISA in
124 samples were similar to the RBA‐based measurements:
the median GAD65Ab concentrations for Ghana and for
Europe were 64.5U/mL (IQR: 54.9‐101.8U/mL) and
58.5U/mL (IQR: 53.2‐68.9U/mL; P= .069), respectively.
The Pearson correlation between the Kronus ELISA and
the RBA was r= .49 with P< .0001. For the DRG ELISA
and the LIPS analysis, we cannot comment on site‐specific
results, because these assays were only performed in sam-
ples from rural Ghana and Berlin, respectively (Table S1).
Yet, as shown in Figure 2, ZnT8Ab concentrations were
also significantly higher in Ghana than in Europe
(P< .0001). ZnT8Ab correlated moderately with GAD65Ab
concentrations (r= .24; P< .0001).
3.3 | Immunoglobulin isotypes and IgG
subclasses
The additional isotype analyses revealed that the most
prevalent serum autoantibody isotype in all study sites
was IgG, with IgG1 being the major subclass (Figure S4).
IgG1 concentrations in samples from Ghana (median
13.4; IQR: 10.9‐16.7 mg/mL) were significantly higher
compared with those from Europe (median: 11.7;
FIGURE 1 GAD65Ab concentrations (U/mL) in 5898
participants by study site
TABLE 1 Proportions of GAD65Ab
positivity by diabetes status and study site
N No diabetes (%) Diabetes (%) P value
Main analysisa
Total 5898 6.1 5.4 .479
Rural Ghana 1111 13.9 14.3 .941
Urban Ghana 1455 8.3 8.9 .824
Europe 3332 2.4 2.6 .826
Sensitivity analysisa
Total 5539 6.1 5.5 .728
Rural Ghana 1082 13.9 14.8 .896
Urban Ghana 1377 8.3 8.8 .907
Europe 3080 2.4 1.0 .380
aFor the main analysis, diabetes was defined as greater than or equal to 7mmol/L or use of
glucose‐lowering medication or self‐reported diabetes. For the sensitivity analysis, we excluded
self‐reported diabetes.
FIGURE 2 ZnT8Ab concentrations (U/mL) in 146
participants from Europe and 141 participants from Ghana. Median
binding and standard deviations are indicated
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IQR: 9.5‐13.6 mg/mL; P< .0001 and Figure S5). This was
also true for IgM (0.56 vs 0.38 mg/mL; P< .0001) and
IgE concentrations (0.20 vs 0.15 mg/mL; P< .0001;
Figure S5). The correlations for GAD65Ab concentrations
with Ig isotypes and IgG subclasses are presented in
Figure S6. IgM, IgG, and IgE levels correlated with
GAD65Ab concentrations in the 316 samples analyzed
for all four parameters. However, when stratified by
study site, only IgM levels correlated with GAD65Ab
concentrations and only in Ghana (r= .28; P= .002).
3.4 | Factors related to GAD65Ab
concentrations
Taken together, GAD65Ab, IgG1, IgE, and IgM concentra-
tions were significantly higher in Ghana than in Europe.
These observations and the fact that other markers of in-
fection were the highest in rural Ghana (Table S2) gave
rise to the hypothesis that GAD65Ab might be related to
an infectious environment. In Table 2, we present the
means of GAD65Ab concentrations, adjusted for important
TABLE 2 Adjusted means for GAD65Ab concentrations (U/mL) according to sociodemographic and clinical factors
Infection‐related factor N
Adjusted means in U/mL
(95% CI): model 1
Adjusted means in U/mL
(95% CI): model 2
Adjusted means in U/mL
(95% CI): model 3
Study site 5898
Rural Ghana 1111 85.0 (78.3, 91.7)* 85.4 (76.5, 94.3)* 84.0 (74.9, 93.1)*
Urban Ghana 1455 58.2 (52.3, 64.2) 61.4 (53.9, 68.9) 60.7 (53.1, 68.3)
Europe 3332 22.0 (18.2, 25.9) 26.8 (21.3, 32.3) 27.3 (21.7, 32.8)
Length of stay in Europe, y 3332
≤10 708 22.3 (18.2, 26.5) 22.8 (17.9, 27.7)
11‐20 1431 21.7 (18.9, 24.6) 22.4 (18.6, 26.1)
21‐30 973 19.9 (16.4, 23.5) 20.5 (16.4, 24.6)
>30 220 25.0 (17.4, 32.5) 25.4 (17.6, 33.2)
Duration of diabetes, y 541
<2 142 31.2 (12.7, 49.7) 28.1 (6.8, 49.3)
2‐5 114 30.9 (10.6, 51.1) 26.1 (3.3, 49.4)
5‐10 118 30.9 (10.9, 50.9) 26.4 (3.8, 49.0)
10‐20 115 40.0 (19.6, 60.4) 34.7 (11.7, 57.7)
≥20 52 55.6 (25.8, 85.8) 50.5 (18.3, 82.8)
Insulin treatment 541
No 459 34.0 (23.8, 44.2) 38.7 (13.1, 64.2)
Yes 82 42.1 (18.1, 66.0) 29.0 (14.0, 44.0)
C‐reactive protein, mg/L 5898
<3.0 1680 45.8 (40.2, 51.4) 39.7 (32.6, 46.7)
3.0‐4.9 3385 40.3 (36.3, 44.3) 41.1 (35.4, 46.8)
5.0‐9.9 488 44.8 (34.4, 55.2) 49.9 (38.7, 61.1)
≥10.0 345 43.6 (21.3, 56.0) 46.4 (33.5, 59.4)
Current fever 5898
No 5611 41.2 (38.1, 44.3)* 40.9 (35.9, 46.1)*
Yes 287 68.2 (54.7, 81.7) 61.5 (47.3, 75.6)
Hx fever in the past 2 wk 5898
No 4997 39.7 (36.4, 42.9)* 40.1 (34.9, 45.3)*
Yes 901 58.9 (51.2, 66.6) 52.8 (43.9, 61.6)
ALAT, U/L 5898
Tertile 1 (≤16.3) 1977 40.9 (35.5, 46.3) 37.9 (31.2, 44.7)
Tertile 2 (16.4‐23.0) 1953 43.9 (38.7, 49.2) 43.4 (36.7, 50.0)
Tertile 3 (≥23.1) 1969 42.5 (37.3, 47.6) 43.5 (37.0, 50.1)
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sociodemographic and clinical factors. Residence in rural
Ghana remained associated with higher GAD65Ab con-
centrations, followed by urban Ghana and Europe. For
infection‐related factors, GAD65Ab concentrations were
higher in individuals who had fever or reported a history of
fever within the past 2 weeks. Also, higher concentrations
of ASAT were associated with higher GAD65Ab con-
centrations. Further, the concentrations of CRP, ALAT, and
ASAT tended to be directly associated with GAD65Ab
concentrations (Table 2). No other clinically relevant fac-
tors, such as insulin treatment and the duration of diabetes,
were associated with GAD65Ab concentrations. The dif-
ferences in GAD65Ab concentrations between study sites
remained when infection‐related factors were added as
potential explanatory variables to sociodemographic and
anthropometric factors.
3.5 | GAD65Ab by diabetes status
Table 1 also presents the proportions of GAD65Ab‐positive
individuals according to diabetes status. In the present
study population, 5.4% of the individuals in the group with
adult‐onset diabetes were GAD65Ab‐positive, while the
proportion of GAD65Ab positivity was 6.1% in the non-
diabetes group (P= .48). In addition, there were no differ-
ences per study site in GAD65Ab positivity between
diabetes and nondiabetes groups. These findings were
confirmed when excluding participants with self‐reported
diabetes (Table 1, bottom panel). The GAD65Ab con-
centrations by diabetes status obtained by the Kronus
ELISA and by the DRG ELISA are shown in Figure 3, and
were similarly distributed between individuals with or
without diabetes. Also, the LIPS analysis showed similar
concentrations of GAD65Ab for individuals with and
without diabetes (median: 1.2 U/mL; IQR: 0.0‐4.8U/mL vs
median: 0.9 U/mL; IQR: 0.0‐4.0U/mL; P= .62). This
translated into 11% (8 out of 70) GAD65Ab‐positive in-
dividuals in the diabetes group and 10% (7 out of 70)
GAD65Ab‐positive participants in the nondiabetes group
(P= .79). For Ig isotypes and IgG subclasses, there were no
differences between individuals with or without diabetes.
Lastly, none of the individuals with diabetes‐onset before
the age of 18 years (n= 11) were GAD65Ab‐positive.
TABLE 2 (Continued)
Infection‐related factor N
Adjusted means in U/mL
(95% CI): model 1
Adjusted means in U/mL
(95% CI): model 2
Adjusted means in U/mL
(95% CI): model 3
ASAT, U/L 5898
Tertile 1 (≤27.6) 1976 29.8 (24.1, 34.9)* 32.1 (25.5, 38.7)*
Tertile 2 (27.7‐36.1) 1960 42.0 (36.8, 47.2) 41.2 (34.5, 47.8)
Tertile 3 (≥36.2) 1962 54.4 (49.3, 59.5) 51.9 (45.3, 58.3)
ASAT/ALAT 5898
≤1.0 434 28.4 (14.5, 39.3)* 33.6 (21.9, 45.4)
>1.0 5464 43.7 (40.5, 46.9) 42.4 (37.2, 47.5)
GGT, U/L 5898
Tertile 1 (≤25.3) 1971 42.3 (36.9, 47.7) 39.3 (32.5, 46.1)
Tertile 2 (25.4‐37.5) 1965 47.0 (41.8, 52.2) 46.3 (39.6, 53.0)




Tertile 1 (≤0.48) 1967 42.3 (36.9, 47.7) 43.0 (36.3, 49.8)
Tertile 2 (0.49‐0.57) 1965 40.0 (34.8, 45.2) 39.8 (33.3, 46.3)
Tertile 3 (≥0.58) 1966 45.1 (39.8, 50.4) 42.3 (35.6, 49.1)
Urinary albumin, mg/L 5898
0‐19.9 5014 42.5 (39.2, 45.8) 41.3 (36.1, 46.6)
20.0‐29.9 277 47.9 (34.2, 61.6) 49.7 (35.6, 63.9)
≥30.0 607 39.5 (30.3, 48.8) 40.9 (30.9, 51.0)
Note: Model 1: linear regression adjusted for age and sex; model 2: linear regression adjusted for age, sex, educational level, smoking status, body mass index,
and waist circumference; model 3: linear regression adjusted for all factors in model 2 and markers of infection.
Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate; GGT,
γ‐glutamyltransferase; MDRD, Modification of Diet in Renal Disease.
*P< .05 for trend.
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4 | DISCUSSION
4.1 | Summary of main results
The present study aimed at determining the potential of
beta‐cell autoantibodies to classify diabetes and to guide
its therapy among 5898 Ghanaian adults. Using a highly
specific detection method for GAD65Ab, surprisingly,
we observed a similar prevalence of GAD65Ab positivity
between individuals with and without adult‐onset
diabetes. There was a geographic trend in GAD65Ab
concentration with the highest concentrations in rural
Ghana, followed by urban Ghana and Europe. However,
this was only partly explained by markers of infection.
4.2 | Strengths and limitations
The present study provides first‐time findings from a large
sub‐Saharan African sample regarding biomarkers of adult‐
onset autoimmune diabetes that have been established in
mainly European populations. Nevertheless, our results
need to be interpreted with caution. Participation in the
study was limited to adults aged 25 to 70 years. Formerly,
individuals with T1D in sub‐Saharan Africa had a poor
prognosis.22 Given that greater than 98% of our middle‐
aged study participants were born in Ghana, only a few
individuals with T1D might have reached the age of in-
clusion. This survival effect could have led to an under-
representation of T1D in our study population, which is
further corroborated by the fact that most of the patients
with diabetes in the present study had an adult age of
disease onset. Hence, such survival effect might, in part,
explain the similar prevalence of GAD65Ab positivity in
diabetes and nondiabetes groups. While genetic informa-
tion for the human leukocyte antigen region influence
GAD65Ab concentrations, these data were not available for
our study population. An important strength of our study is
the comprehensive set of analyses to test the robustness of
our results. We confirmed the specificity of GAD65Ab
measurement by competition assays yielding 78% sensi-
tivity and 70% specificity, and by the identification of Ig
isotypes and IgG subclasses. We verified the differential
proportions of GAD65Ab positivity according to diabetes
status by two different ELISAs, by LIPS analysis in an in-
dependent laboratory, and after excluding individuals with
self‐reported diabetes. Further, we had a range of objec-
tively measured and self‐reported infection‐related factors
at hand to identify their relationships with GAD65Ab
concentrations.
4.3 | GAD65Ab concentrations,
ethnicity, and diabetes status
Previous reports indicate that the occurrence of GAD65Ab
and their association with diabetes is ethnicity specific.
The prevalence of GAD65Ab positivity in individuals
without diabetes spans from 1% in Greenland Inuit
through 2% to 3% in individuals with European descent up
to 1% to 7% in non‐Hispanic blacks.23‐26 While Caucasian
and Asian populations report 80% to 90% autoantibody
positivity in T1D patients,27,28 only 36% to 44% of T1D
patients living in sub‐Saharan Africa tested positive for
FIGURE 3 GAD65Ab concentrations (U/mL) using the
radioligand binding assay (RBA) and two enzyme‐linked
immunosorbent assays (ELISA). GAD65Ab titers (U/mL) obtained
by Kronus ELISA in 124 samples (A, left), by RBA in 124 samples
(A, right), and by DRG ELISA in 84 samples (B). Numbers indicate
median (percentile 25‐percentile 75)
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islet cell autoantibodies13,29 and much lower frequencies
(7%‐9%) were observed in T1D patients residing in
Nigeria.30 This disconnect between T1D and auto-
antibodies was also observed in African Americans diag-
nosed with T1D,31 suggesting a strong ethnical factor in
the development of beta‐cell autoantibodies. The associa-
tion between GAD65Ab and diabetes can also be observed
in patients diagnosed with adult‐onset diabetes in Europe,
where the respective proportions reach differences of 1 to
4 percentage points.25,26 However, this is not uniformly
seen for individuals from sub‐Saharan Africa.11,23 For
African Americans in the Third National Health and
Nutrition Examination Survey, there was only a trend for
differences in GAD65Ab positivity between diabetes and
nondiabetes groups (3.7% vs 1.3%; P= .08), whereas the
figures for non‐Hispanic whites were clearly distinct: 6.3%
vs 2.0%; P= .001.23 However, a small study from Kumasi,
Ghana (n = 120) reported that 18% of patients with
insulin‐dependent diabetes, 9% of patients with non‐
insulin–requiring diabetes, and 2% of individuals without
diabetes were positive for GAD65Ab.11 In that study, the
patients were adults with new‐onset diabetes (mean age:
48.2 ± 13.4 years; disease duration <1 year), and
GAD65Ab was measured by an ELISA developed by DRB
International Inc. Notably, this assay uses anti‐human
IgG for the detection of the GAD65‐human antibody
complexes. The RBA in the present study and the KRO-
NUS ELISA kit cannot discriminate between different Ig
isotypes. It was, therefore, possible that the highly reactive
IgM antibody interfered with the specific detection of
GAD65 antibodies of the IgG isotype in the RBA. This is
supported by our finding that IgM concentrations corre-
lated with GAD65Ab. However, our analysis in a subset of
diabetes and nondiabetes groups using the DRB ELISA kit
showed no significant differences for GAD65Ab con-
centration between the two groups. Moreover, the results
obtained by the DRB ELISA correlated significantly with
the GAD65Ab measured by the RBA, suggesting that a
substantial proportion of GAD65Ab are of the IgG isotype.
Therefore, the discrepancies between the earlier study in
Kumasi and ours might stem from differential population
characteristics and sample size constraints in the study by
Agyei‐Frempong et al.11 Taken together, our data suggest
that GAD65Ab may not differentiate between auto-
immune and nonautoimmune diabetes in specific ethnic
subgroups.
4.4 | Infectious environment
and GAD65Ab
The different distributions of GAD65Ab across study
sites were striking, and we hypothesized that exposure to
infectious environments could contribute to this ob-
servation. IgM concentrations were the highest in rural
Ghana, and only there, IgM moderately correlated posi-
tively with GAD65Ab. High IgM concentrations char-
acterize acute and recurrent infections.32 In sub‐Saharan
Africa, infectious diseases, such as malaria, still con-
stitute a major public health challenge.33 Malaria is ty-
pically more prevalent in rural settings, and the humoral
response against the malaria parasite Plasmodium falci-
parum is dominated by high IgG and IgM serum levels.34
Surprisingly, only a fraction of these antibodies are spe-
cific to malaria antigens, while the majority is polyclonal,
showing reactivity to rheumatoid factor and antinuclear
specificity.35 Importantly, the antibody concentrations
remain high even after the curation of clinical malaria
but are inversely correlated with years of residence in
endemic areas.35,36 Moreover, infections with parasites,
such as Plasmodium sp., are known to initiate auto-
immune responses in previously nonautoimmune in-
dividuals.37 The effect of an infectious environment on
the production of autoantibodies was elegantly illustrated
by the prevalence of antinuclear autoantibodies (ANA)
among migrants from Nigeria and Ghana to Italy.20
These individuals showed significantly higher ANA
concentrations than the Italian reference population, but
the prevalence strongly decreased after longer length of
residence in Italy (≥8 years). This was not as clearly seen
in our study population, where 88% of individuals had
been living in Europe for more than 10 years. Also, the
different GAD65Ab concentrations between Ghana and
Europe remained discernible even after inclusion of
infection‐related factors in the final regression model. In
fact, the low proportions of GAD65Ab positivity in the
European sites of the present study population resemble
those observed in the European Prospective Investigation
into Cancer and Nutrition (EPIC)‐InterAct study in the
same countries.26 Therefore, we speculate that alternative
environmental factors such as higher exposure to air
pollution, vaccines, family environment, and stress in
Ghana as compared with Europe might be involved.38
Therefore, GAD65Ab does not serve as a specific marker
for autoimmune diabetes in this sub‐Saharan African
population.
5 | CONCLUSIONS
Pending verification in independent sub‐Saharan
African populations, our findings may have important
implications for clinical management and health care
planning for these population groups. Our results high-
light the need to validate established markers for auto-
immune diabetes in different ethnic populations and to
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develop new ones. Until then, for the growing group of
migrants from sub‐Saharan Africa to Europe, other fac-
tors than autoimmune status may be more relevant for
efficient and effective disease management and for
the identification of novel diabetes subgroups.
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